Cellectis U.S. Listed Shares up 3.5% at $2.66 After the Bell After Receives Orphan Drug Designation for Allogeneic Car T Product for Patients With Acute Lymphoblastic Leukemia
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.